scholarly journals Safety and Tolerability of Donepezil, Rivastigmine and Galantamine for Patients with Alzheimer’s Disease: Systematic Review of the ‘Real-World’ Evidence

2009 ◽  
Vol 28 (5) ◽  
pp. 389-403 ◽  
Author(s):  
I.A. Lockhart ◽  
S.A. Mitchell ◽  
S. Kelly
Keyword(s):  
Systematic Review ◽  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Real World ◽  
The Real ◽  
Real World Evidence

Systematic review of the real-world evidence of adalimumab safety in psoriasis registries

2018 ◽  
Vol 32 (12) ◽  
pp. 2126-2133 ◽  
Author(s):  
B. Strober ◽  
J. Crowley ◽  
R.G. Langley ◽  
K. Gordon ◽  
A. Menter ◽  
...  
Keyword(s):  
Systematic Review ◽  
Real World ◽  
The Real ◽  
Real World Evidence

Risk of Alzheimer's Disease in Obstructive Sleep Apnea Patients With or Without Treatment: Real‐World Evidence

2020 ◽  
Vol 130 (9) ◽  
pp. 2292-2298 ◽  
Author(s):  
Ming‐Shao Tsai ◽  
Hsueh‐Yu Li ◽  
Chung‐Guei Huang ◽  
Robert Y.L. Wang ◽  
Li‐Pang Chuang ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Obstructive Sleep Apnea ◽  
Sleep Apnea ◽  
Real World ◽  
Real World Evidence ◽  
Obstructive Sleep

OP170 Regulatory And Health Technology Assessment Considerations In Alzheimer's Disease

2018 ◽  
Vol 34 (S1) ◽  
pp. 61-62
Author(s):  
Jacoline Bouvy ◽  
Pall Jonsson
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Health Technology Assessment ◽  
Technology Assessment ◽  
Real World ◽  
Data Access ◽  
Health Technology ◽  
Advisory Group ◽  
Real World Evidence ◽  
Disease Modifying

Introduction:There has been a move towards the development of disease-modifying agents in Alzheimer's disease (AD) and it is likely that early disease-modifying treatments will initially be offered to people who have positive AD markers and mild cognitive impairment (MCI). Consequently, disease-modifying drugs will have distinctive features as compared to currently licensed symptomatic treatments, which makes the implications of these new agents for regulatory and health technology assessment (HTA) processes unclear.Methods:The ROADMAP (Real-world Outcomes across the AD spectrum for better care: Multi-modal data Access Platform) project provides the foundation for a European data platform for real-world evidence in AD, and established an expert advisory group (EXAG) consisting of regulatory and HTA experts. This presentation will summarize the key lessons from the first year of ROADMAP's EXAG and identifies the next steps that are required to prepare Europe's healthcare systems for a disease-modifying drug.Results:The EXAG identified a need for: (i) establishing the rationale for the selection of priority outcomes in pre-clinical AD and MCI; (ii) establishing accepted outcomes for defining prevention of AD or delayed AD onset; (iii) exploring modern technology that could assist in testing cognition that could easily be used in clinical practice; and (iv) establishing caregiver-relevant outcomes (e.g. quality of life, loss of income, carer time) that are important to capture; and found that not all evidence to support modelling assumptions can be generated through RCTs, making the case for using real-world evidence.Conclusions:Many of the challenges that the EXAG identified can be solved by generating better real-world data in AD. There is a clear need to agree on the outcomes that will facilitate and inform regulatory and HTA decision-making. Once the gaps in the availability of outcomes in AD will be closed, we will be one step closer towards being ready for a disease-modifying drug.

scholarly journals Experimental and real-world evidence supporting the computational repurposing of bumetanide for APOE4-related Alzheimer’s disease

Nature Aging ◽  
2021 ◽  
Vol 1 (10) ◽  
pp. 932-947
Author(s):  
Alice Taubes ◽  
Phil Nova ◽  
Kelly A. Zalocusky ◽  
Idit Kosti ◽  
Mesude Bicak ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Real World ◽  
Real World Evidence

scholarly journals Real‐world evidence in Alzheimer's disease: The ROADMAP Data Cube

2020 ◽  
Vol 16 (3) ◽  
pp. 461-471 ◽  
Author(s):  
Olin Janssen ◽  
Stephanie J. B. Vos ◽  
Glòria García‐Negredo ◽  
Claire Tochel ◽  
Anders Gustavsson ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Real World ◽  
Data Cube ◽  
Real World Evidence

scholarly journals Challenges in Optimising Real World Evidence for Alzheimer’s Disease

2017 ◽  
Vol 20 (9) ◽  
pp. A404
Author(s):  
C Reed ◽  
F de Reydet de Vulpillieres ◽  
J Gallacher
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Real World ◽  
Real World Evidence
Sign in / Sign up

Export Citation Format

Share Document